Antibody constructs for CDH19 and CD3

US11498964B2 · kind B2 · utility

Assignees

• AMGEN RESEARCH (MUNICH) GMBH · DE
• AMGEN INC. · US

Inventors

• Shouhua Xiao · Foster City, US
• Zheng Pan · Beijing, CN
• Dineli Wickramasinghe · San Francisco, US
• M. Shawn Jeffries · Indianapolis, US
• Chadwick Terence King · North Vancouver, CA
• Brian Mingtung Chan · Port Coquitlam, CA
• Peter Kufer · Munich, DE
• Ralf Lutterbüse · Munich, DE
• Tobias Raum · Munich, DE
• Patrick Hoffmann · Munich, DE
• Doris Rau · Munich, DE
• Roman Kischel · Munich, DE
• Bryan D. LEMON · Mountain View, US
• Holger Wesche · San Francisco, US

Key dates

• Filing date: Jul 20, 2018
• Grant date: Nov 15, 2022
• Expiry date: Nov 3, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.